Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about MGRX, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
MGRX holds $228,688 in cash and short-term investments (as of Jun 30, 2026) and burns about $785,925/quarter from operations, an estimated runway of 0.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 90 · High
These factors raise substantial doubt about the ability of the Company to continue as a going concern.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MGRX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Armistice Capital, LLC | Institution (13F) | 1,536,000 | 6.91% | 2025-12-31 |
| Jacob D. Cohen Chief Executive Officer, Director, 10% o · +3.43M options |
Insider | 605,000 | 2.72% | 2026-03-16 |
| Vanguard Group Inc | Institution (13F) | 489,532 | 2.20% | 2025-12-31 |
| Eugene M Johnston CFO |
Insider | 220,000 | 0.99% | 2026-07-28 |
| Amanda Elizabeth Hammer Chief Operating Officer |
Insider | 175,000 | 0.79% | 2024-06-03 |
| Ikarian Capital, LLC | Institution (13F) | 138,146 | 0.62% | 2025-12-31 |
| Lorraine Pamela D'Alessio Director |
Insider | 136,667 | 0.61% | 2025-09-09 |
| Kenny Myers Director |
Insider | 136,667 | 0.61% | 2025-09-09 |
| Geode Capital Management, LLC | Institution (13F) | 108,322 | 0.49% | 2025-12-31 |
| Alex P. Hamilton Director |
Insider | 101,667 | 0.46% | 2026-07-28 |
| Antonios Isaac President, Director |
Insider | 60,000 | 0.27% | 2025-04-10 |
| Jane Street Group, LLC | Institution (13F) | 47,503 | 0.21% | 2025-12-31 |
Share count 22,224,420 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2025-12-31). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-03-16 filed 2026-03-20 |
Cohen Jacob D. |
Option award (A) | 2,000,000 | – | – |
| 2026-03-16 filed 2026-03-20 |
Cohen Jacob D. |
Returned to issuer (D) | 2,000,000 | – | – |
| 2026-03-16 filed 2026-03-20 |
Cohen Jacob D. |
Option award (A) | 83,333 | – | – |
| 2026-03-16 filed 2026-03-20 |
Cohen Jacob D. |
Returned to issuer (D) | 83,333 | – | – |
| 2026-03-16 filed 2026-03-20 |
Cohen Jacob D. |
Option award (A) | 50,000 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MGRX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →